Our publications

Personalise
Stack and pile of books on table in public or school library.
  1. Faten Shehadeh-Tout, Heloisa H Milioli, Suraya Roslan, Patric J Jansson, Mahendiran Dharmasivam, Dinny Graham, Robin Anderson, Tharushi Wijesinghe, Mahan Gholam Azad, Des R Richardson, Zaklina Kovacevic (2023) An Innovative Non-Hormonal Strategy Targeting Redox Active Metals to Down-Regulate Estrogen-, Progesterone-, Androgen- and Prolactin-Receptors in Breast Cancer. Pharmacol. Res. 193:106806.
  2. Jiawei Chang, Zoe H. Y. Lo, Shafi Alenizi and Zaklina Kovacevic (2023) Re-shaping the pancreatic cancer tumor microenvironment: A new role for the metastasis suppressor NDRG1. Cancers 15 (10), 2779 (doi: 10.3390/cancers15102779).
  3. Bekesho Geleta, Faten S. Tout, Syer Choon Lim, Sumit Sahni, Patric J. Jansson, Minoti V. Apte, Des R. Richardson, and Žaklina Kovačević (2022) The Mechanism of Targeting Wnt/Tenascin C-Mediated Cross-Talk between Pancreatic Cancer Cells and Stellate Cells via the Metastasis Suppressor, NDRG1. JBC 298(3):101608.
  4. Syer C. Lim, Bekesho Geleta, Sanaz Maleki, Des R. Richardson and Zaklina Kovacevic (2021) The Metastasis Suppressor, NDRG1, Directly Regulates Androgen Receptor Signaling in Prostate Cancer. JBC 297(6):101414.
  5. Bekesho Geleta, Kyung Chan Park, Patric J. Jansson, Sumit Sahni, Sanaz Maleki, Zhihong Xu, Takashi Murakami, Marina Pajic, Minoti V. Apte, Des R. Richardson and Zaklina Kovacevic (2021) Breaking the cycle: Targeting NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma. FASEB J 35(2):e21347.
  6. Syer C. Lim, Patric J. Jansson, Stephen Assinder, Sanaz Maleki, Des R. Richardson and Zaklina Kovacevic (2020) Unique targeting of androgen-dependent and independent AR signaling in prostate cancer to overcome androgen resistance. FASEB J 34(9):11511-11528. 3 citations.
  7. Sundus N. Maqbool, Syer C. Lim, Rumeza Hanif, Des R. Richardson, Patric J. Jansson and Zaklina Kovacevic (2020) Overcoming tamoxifen resistance in estrogen receptor positive breast cancer using a novel class of thiosemicarbazone anti-cancer agents. British J. Pharmacology 177(10):2365-2380. 

Publications